MIFH
AQST icon

Migdal Insurance & Financial Holdings’s Aquestive Therapeutics AQST Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,502
Closed -$6K – 603
2021
Q4 		$6K Sell
1,502
-904
-38% -$4.54K ﹤0.01% 636
2021
Q3 		$10K Buy
+2,406
New +$9.43K ﹤0.01% 593

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
GL
Graypoint LLC Albany, New York $1.78B AUM 16.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LI
Latash Investments Anchorage, Alaska $129M AUM 14.69% 1-Year Est. Return

Migdal Insurance & Financial Holdings's AQST Position: Q1 2022 in Review

Migdal Insurance & Financial Holdings sold out of Aquestive Therapeutics (AQST) in Q1 2022, closing a stake of 1,502 shares — an estimated $6K sold.

Migdal Insurance & Financial Holdings first reported a position in AQST in Q3 2021 and held it in 2 quarters. The position peaked at $10K in Q3 2021. 51 funds tracked by Wall St. Rank hold AQST as of Q1 2022.

  • Migdal Insurance & Financial Holdings reported no remaining Aquestive Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Migdal Insurance & Financial Holdings sold 1,502 Aquestive Therapeutics shares in Q1 2022, an estimated $6K.
  • Migdal Insurance & Financial Holdings first reported a position in Aquestive Therapeutics in Q3 2021 and held it in 2 quarters.
  • Migdal Insurance & Financial Holdings's Aquestive Therapeutics position peaked at $10K in Q3 2021.
  • 51 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2022.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q1 2022, filed 2 May 2022.